Anthem, Nation’s Second Major Health Approach, Now Addresses Hologic’s Acessa Process as a Procedure for Uterine Fibroids

MARLBOROUGH, Mass.–(Organization WIRE)–Hologic, Inc. (Nasdaq: HOLX), a world leader in women’s wellbeing, declared these days…

MARLBOROUGH, Mass.–(Organization WIRE)–Hologic, Inc. (Nasdaq: HOLX), a world leader in women’s wellbeing, declared these days that Anthem Blue Cross Blue Shield, the second greatest well being approach in the United States, has up-to-date its clinical plan to include Radiofrequency Ablation (LAP-RFA), which involves the Acessa® process (CPT Code 58674), for ladies suffering from uterine fibroids. The updated plan generates access to uterine-preserving care for Anthem’s about 40 million customers in all 50 states, giving a safe and successful option for millions of ladies who normally may have to vacation resort to unwanted hysterectomies.

Anthem’s updated healthcare policy says the use of laparoscopic or transcervical radiofrequency ablation as a treatment for symptomatic uterine fibroids (e.g. excessive uterine bleeding or pelvic soreness prompted by uterine fibroids) is deemed medically needed when uterine preservation is sought after, fibroids are significantly less than 10 cm in any diameter and uterine size does not exceed 16 weeks gestation.1

“Women’s well being problems remain chronically underserved and this has by no means been extra apparent than with the millions of women residing with uterine fibroids,” mentioned Essex Mitchell, Division President GYN Surgical Answers, Hologic. “Anthem’s decision will make appreciably increased accessibility to possibilities that align with the robust preferences quite a few women and their medical professionals have for harmless and powerful therapy that enables the two symptom reduction and uterine preservation.”

An believed 11 million girls in the United States are at this time diagnosed with uterine fibroids, with an additional 3.7 million undiagnosed females self-identified as having symptoms suggestive of uterine fibroids.2 Up to 80% of women are diagnosed with uterine fibroids by the age of 50.3 Females with symptomatic uterine fibroids frequently worry getting rid of their uterus due to the fact of hysterectomy but are both not supplied or in a position to afford non-reimbursed option treatment method options. This leaves much too quite a few women of all ages seriously burdened by their fibroid signs and symptoms, top to a lessened quality of daily life.4 Black girls are disproportionately impacted by fibroids, making accessibility to fibroid therapy a critical focus in the hard work to address racial disparities in health care.

“I have personally handled dozens of girls who needed this treatment but had to select a further solution due to the fact it was not protected by their insurance,” said Dr. Soyini Hawkins, a minimally invasive gynecologist who established and prospects the Fibroid and Pelvic Centre of Ga. “Anthem’s final decision is fantastic and will not only boost the wellbeing outcomes for females but also enable their preferences to be honored.”

The Acessa process is a minimally invasive, outpatient treatment designed to take care of women with symptomatic uterine fibroids and is clinically verified with very long-phrase information as a harmless alternative to hysterectomy and myomectomy.5,6 Women knowledge minimum discomfort following the treatment and commonly return to operate in four to five times.5 For much more details about the positive aspects and pitfalls of the Acessa process, visit www.gynsurgicalsolutions.com

About Hologic

Hologic, Inc. is an revolutionary professional medical technologies organization mainly targeted on increasing women’s overall health and very well-currently being as a result of early detection and remedy. For extra facts on Hologic, go to www.hologic.com.

Forward-On the lookout Statements

This press launch might consist of ahead-looking facts that consists of pitfalls and uncertainties, like statements about the use of Hologic’s Acessa product. There can be no assurance this products will realize the positive aspects described herein or that these benefits will be replicated in any unique method with respect to an individual individual. The true outcome of the use of the item can only be determined on a situation-by-situation basis dependent on the specific conditions and affected individual in dilemma. In addition, there can be no assurance that this item will be commercially productive or realize any anticipated stage of gross sales. Hologic expressly disclaims any obligation or undertaking to launch publicly any updates or revisions to any this kind of statements offered herein to replicate any improve in expectations or any change in functions, problems, or situations on which any these kinds of statements are based mostly.

Hologic, Acessa, and The Science of Absolutely sure are emblems and/or registered emblems of Hologic, Inc. and/or its subsidiaries in the United States and/or other nations.

Sources

  1. SURG.00077. Anthem Blue Cross Blue Protect: Well being Insurance policy, Medicare & More. (2021, August 19). https://www.anthem.com/dam/medpolicies/abcbs/energetic/policies/mp_pw_a053391.html.
  2. Marsh EE, Al-Hendy A, Kappus D, Galitsky A, Stewart EA, Kerolous M. Stress, Prevalence, and Treatment method of Uterine Fibroids: A Survey of U.S. Gals. J Womens Overall health. 201827(11):1359-1367.
  3. Coyne KS, Harrington A, Currie BM, Chen J, Gillard P, Spies JB. Psychometric validation of the 1-month remember Uterine Fibroid Symptom and Wellbeing-Associated Good quality of Existence questionnaire (UFS-QOL). J Patient-Rep Outcomes. 20193(1):57.
  4. Giuliani E, As‐Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Gynecol Obstet. 2020149(1):3-9.
  5. SG Chudnoff, et al. Outpatient Technique for the Procedure and Relief of Symptomatic Uterine Myomas. Obstetrics and Gynecology, 2013121(5):1075–82.
  6. Yelena Havryliuk, MD, Robert Setton, MD, John Carlow, EdD, MPH, Barry D. Shaktman, MD, Management of symptomatic fibroids: overview and meta-analysis of the literature (2006 -2016), Journal of the Modern society of Laparoendoscopic Surgeons, Vol. 21 (3) Jul-Sept 2017

Notes and Disclaimers

Important Protection Details The Acessa ProVu technique is indicated for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including cure of symptomatic uterine fibroids underneath laparoscopic ultrasound direction. The Acessa ProVu system is contraindicated for patients who are not candidates for laparoscopic surgery and/or sufferers with a uterus adherent to pelvic tissue or viscera. The Acessa ProVu system’s steering process is not meant for diagnostic use. You should browse all guidelines for use of the Acessa ProVu system prior to its use. Risk-free and helpful electrosurgery is dependent not only on gear style and design but also on factors below management of the operator. Scarce but major pitfalls include, but are not minimal to, an infection, damage to adjacent structures, blood loss and complications linked to laparoscopy and/or basic anesthesia. Insufficient knowledge exists on which to examine the safety and success of the Acessa ProVu system in girls who approach long term pregnancy, for that reason the Acessa ProVu method is not encouraged for women who are preparing future being pregnant.

Resource Hologic, Inc.